Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:BETRFNASDAQ:CNTBOTCMKTS:ETSTNASDAQ:LIAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBETRFBetterLife Pharma$0.08-3.9%$0.06$0.05▼$0.15$10.49M1.4718,110 shs10,530 shsCNTBConnect Biopharma$0.76-8.4%$0.74$0.51▼$2.07$41.79M-0.356,221 shs84,790 shsETSTEarth Science Tech$0.14-0.1%$0.14$0.00▼$0.33$41.26M1.92110,035 shs12,800 shsLIANLianBio$0.36-5.3%$0.21$0.27▼$4.99$38.91M0.231.04 million shs17,901 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBETRFBetterLife Pharma0.00%+20.00%+19.12%-1.58%-7.11%CNTBConnect Biopharma0.00%+0.53%-2.39%-13.23%-55.59%ETSTEarth Science Tech0.00%-17.65%-17.65%-15.66%-46.15%LIANLianBio-5.25%-5.23%+89.70%+80.03%+14.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBETRFBetterLife Pharma0.7946 of 5 stars0.05.00.00.01.41.70.0CNTBConnect Biopharma2.8696 of 5 stars3.55.00.00.01.12.50.6ETSTEarth Science TechN/AN/AN/AN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBETRFBetterLife Pharma 0.00N/AN/AN/ACNTBConnect Biopharma 3.00Buy$8.00959.60% UpsideETSTEarth Science Tech 0.00N/AN/AN/ALIANLianBio 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BETRF, CNTB, ETST, and LIAN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/31/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBETRFBetterLife PharmaN/AN/AN/AN/A($0.05) per shareN/ACNTBConnect Biopharma$26.03M1.61N/AN/A$1.83 per share0.41ETSTEarth Science Tech$11.95M3.45N/AN/A$0.01 per share14.00LIANLianBioN/AN/AN/AN/A$2.71 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBETRFBetterLife Pharma-$2.14M-$0.03N/A∞N/AN/AN/A-999.57%5/27/2025 (Estimated)CNTBConnect Biopharma-$59.50MN/A0.00N/AN/AN/AN/AN/AN/AETSTEarth Science Tech$810KN/A0.00∞N/AN/AN/AN/AN/ALIANLianBio-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/ALatest BETRF, CNTB, ETST, and LIAN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CNTBConnect Biopharma-$0.26-$0.19+$0.07-$0.19N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBETRFBetterLife PharmaN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AETSTEarth Science TechN/AN/AN/AN/AN/ALIANLianBioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBETRFBetterLife PharmaN/A0.050.05CNTBConnect BiopharmaN/A12.04N/AETSTEarth Science Tech0.010.871.09LIANLianBioN/A10.0610.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBETRFBetterLife Pharma0.01%CNTBConnect Biopharma58.72%ETSTEarth Science TechN/ALIANLianBio74.85%Insider OwnershipCompanyInsider OwnershipBETRFBetterLife Pharma34.77%CNTBConnect Biopharma22.60%ETSTEarth Science Tech24.90%LIANLianBio7.59%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBETRFBetterLife Pharma7129.46 million84.45 millionNot OptionableCNTBConnect Biopharma11055.35 million42.77 millionOptionableETSTEarth Science Tech3294.30 million223.35 millionNot OptionableLIANLianBio110108.06 million99.86 millionNot OptionableBETRF, CNTB, ETST, and LIAN HeadlinesRecent News About These CompaniesHead-To-Head Comparison: BioRestorative Therapies (OTCMKTS:BRTX) versus LianBio (NASDAQ:LIAN)May 24 at 3:47 AM | americanbankingnews.comMeiraGTx Holdings PLCMay 3, 2025 | marketwatch.comWith Kezar stranded in lupus limbo, Concentra spies opportunity for next acquisitionOctober 9, 2024 | fiercebiotech.comChina's Zeekr prices US IPO at top of range to raise $441 millionMay 10, 2024 | msn.comExclusive-China's Zeekr prices US IPO at top of range to raise $441 million, source saysMay 9, 2024 | msn.comWhy Is LianBio (LIAN) Stock Moving Today?March 15, 2024 | investorplace.comLianBio Announces Voluntarily Delisting from NasdaqFebruary 28, 2024 | globenewswire.comWith No Cure In Sight, Drugs Firm LianBio Begins Exit StrategyFebruary 23, 2024 | seekingalpha.comLianBio to shut down, return cash to investorsFebruary 14, 2024 | biopharmadive.comLianBio Announces Wind Down Of Operations, Workforce Reduction; Stock Up In Pre-MarketFebruary 13, 2024 | markets.businessinsider.comLianBio to Wind Down Operations, Declares Special DividendFebruary 13, 2024 | marketwatch.comLianBio Shares Gain After Co Announces Plans to Wind DownFebruary 13, 2024 | marketwatch.comLianBio Announces Completion of Strategic ReviewFebruary 13, 2024 | finance.yahoo.comB of A Securities Downgrades LianBio: Here's What You Need To KnowJanuary 3, 2024 | markets.businessinsider.comNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | markets.businessinsider.comLianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsDecember 26, 2023 | finance.yahoo.comInterest Is Growing for Smaller, More Speculative NamesDecember 20, 2023 | realmoney.thestreet.comLianBio Announces Departure of Chief Financial OfficerDecember 20, 2023 | finance.yahoo.comLianBio Names Stone as Interim CEO as Wang ResignsDecember 19, 2023 | marketwatch.comLianBio Announces Departure of Chief Executive OfficerDecember 19, 2023 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBETRF, CNTB, ETST, and LIAN Company DescriptionsBetterLife Pharma OTCMKTS:BETRF$0.08 0.00 (-3.91%) As of 05/23/2025 09:55 AM EasternBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Connect Biopharma NASDAQ:CNTB$0.76 -0.07 (-8.37%) Closing price 05/23/2025 03:59 PM EasternExtended Trading$0.77 +0.02 (+1.99%) As of 05/23/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Earth Science Tech OTCMKTS:ETST$0.14 0.00 (-0.14%) As of 05/23/2025 03:54 PM EasternEarth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.LianBio NASDAQ:LIAN$0.36 -0.02 (-5.26%) As of 05/23/2025LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
